Skip to main content
Business Of Biotech

Company Turnarounds And AI For Infectious Diseases With Seek Labs' Jared Bauer

56 min episode · 2 min read
·
Seek Labs' Jared Bauer

Episode

56 min

Read time

2 min

Topics

Career Growth, Productivity, Health & Wellness

AI-Generated Summary

Key Takeaways

  • Company Turnaround Framework: Identify failing companies by finding distressed investors, acquire institutional knowledge holders immediately by offering equity stakes, and reframe regulatory agencies as partners rather than adversaries. At BurnFree, this approach expanded distribution from a struggling base to 58 countries across four years before a successful 2016 exit to a larger competitor.
  • Culture-First Hiring: Every candidate at SeekLabs, regardless of seniority, answers the same four questions focused entirely on worldview and personal ambition rather than technical qualifications. Candidates who fail the culture screen are rejected regardless of resume strength. SeekLabs also provides five paid volunteer days annually to reinforce principle-based culture over rule-based compliance.
  • AI Target Discovery Speed: SeekLabs' BioSeqr system maps 145 infectious diseases across 69,000+ influenza strains and roughly 3 billion data points, cross-referenced against 170,000 organisms to eliminate off-target risks. What previously required four years of manual target identification for a single virus can now be completed within hours, enabling rapid therapeutic and diagnostic development across multiple pathogens simultaneously.
  • CRISPR Viral Load Reduction vs. Gene Editing: SeekLabs' PTAP platform uses CRISPR not to edit host genes but to chop up and eliminate viral DNA and RNA directly, lowering viral load so the immune system can respond faster. In African swine fever trials, surviving animals developed natural antibodies and achieved 100% survival upon rechallenge without receiving a second therapeutic dose.
  • Platform Company Focus Discipline: Platform biotechs frequently fail by attempting to pursue every possible application simultaneously. SeekLabs structures its pipeline into three distinct tracks: internally developed and commercialized programs, co-development or sponsored research partnerships with pharma and animal health companies, and direct licensing deals, ensuring capital and scientific resources concentrate on defined, data-supported programs rather than diffuse exploration.

What It Covers

Jared Bauer, cofounder and CEO of SeekLabs, details how personal loss drove him to build an AI-powered infectious disease company, covering the BioSeqr platform mapping 145 diseases across 3 billion data points, a CRISPR therapeutic that raised African swine fever survival from 0% to 60%, and a three-part commercialization strategy.

Key Questions Answered

  • Company Turnaround Framework: Identify failing companies by finding distressed investors, acquire institutional knowledge holders immediately by offering equity stakes, and reframe regulatory agencies as partners rather than adversaries. At BurnFree, this approach expanded distribution from a struggling base to 58 countries across four years before a successful 2016 exit to a larger competitor.
  • Culture-First Hiring: Every candidate at SeekLabs, regardless of seniority, answers the same four questions focused entirely on worldview and personal ambition rather than technical qualifications. Candidates who fail the culture screen are rejected regardless of resume strength. SeekLabs also provides five paid volunteer days annually to reinforce principle-based culture over rule-based compliance.
  • AI Target Discovery Speed: SeekLabs' BioSeqr system maps 145 infectious diseases across 69,000+ influenza strains and roughly 3 billion data points, cross-referenced against 170,000 organisms to eliminate off-target risks. What previously required four years of manual target identification for a single virus can now be completed within hours, enabling rapid therapeutic and diagnostic development across multiple pathogens simultaneously.
  • CRISPR Viral Load Reduction vs. Gene Editing: SeekLabs' PTAP platform uses CRISPR not to edit host genes but to chop up and eliminate viral DNA and RNA directly, lowering viral load so the immune system can respond faster. In African swine fever trials, surviving animals developed natural antibodies and achieved 100% survival upon rechallenge without receiving a second therapeutic dose.
  • Platform Company Focus Discipline: Platform biotechs frequently fail by attempting to pursue every possible application simultaneously. SeekLabs structures its pipeline into three distinct tracks: internally developed and commercialized programs, co-development or sponsored research partnerships with pharma and animal health companies, and direct licensing deals, ensuring capital and scientific resources concentrate on defined, data-supported programs rather than diffuse exploration.

Notable Moment

SeekLabs' African swine fever study began not as a commercial priority but as a controlled proof-of-concept: researchers deliberately chose a disease with a 100% animal mortality rate so that any survivors would provide unambiguous evidence that lowering viral load through CRISPR actually supports immune recovery.

Know someone who'd find this useful?

Episode Transcript

Welcome back to the business of biotech. I'm your host, Ben Comer, chief editor at Life Science Leader. And today, I'm speaking with Jared Bauer, cofounder and CEO at SeekLabs, an AI driven biotech focused on discovering new genetic targets for infectious diseases globally, as well as developing point of care molecular diagnostics and programmable therapies to treat those infectious diseases. SeekLabs has partnered with government agencies such as the Defense Advanced Research Projects Agency or DARPA through the agency's DARPA Connect program and the US Department of Defense's medical CBRN or chemical, biological, radiological, and nuclear defense consortium, as well as the global African swine fever research alliance. Speaking of which, SeekLab's published an interesting paper on a CRISPR based therapeutic for African swine fever last November, which we'll talk about. Jared came to the biotech industry indirectly with a desire to turn around failing companies, a trick he managed to pull off previously with Exxero Medical. I'm excited to chat with Jared about what it takes to turn around a company, why he decided to focus on infectious diseases with Seek Labs, how a technology convergence helped create the company's gene ablation platform, and the role that corporate culture and service plays in a company's health. Thank you so much for being here, Jared. Pleasure to be here, Ben. Thanks for your time. Thanks for joining. You did a short stint at Apple prior to ending entering your MBA program at Boise State, University. I don't have a lot of folks on the podcast that worked for Apple even briefly. I wonder if you could tell me what that was like. So it was a brief stint at Apple, but it was cool. It was a bucket list item for me. I've always been I I am one of those Mac fanboys. I fall deep into that category. Used to spend time on Mac rumors and Mac daily news to see what are they gonna announce next. So when I had a chance to work for Apple, I jumped at that opportunity. I'll just give you kind of two quick anecdotes from my time at Apple. So I got to spend a fair bit of time in Cupertino. And on one of those trips, we got, it was actually for the iPad launch. There was an email that went out late, late at night and it was from Steve Jobs and it was company wide. And so, and and I opened the email immediately. I'd never received an email from Steve Jobs, so I was pretty excited about that. Popped it open and he was inviting us to a town hall. And so the very next morning, I woke up at probably 5AM and drove over to the campus, the old campus, and walked into their town hall, which is what they call their auditorium. Stood in line. I was probably five or number five or six, standing in line and got to go in and hear from …

Get the full transcript (10,137 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Business Of Biotech transcripts →

You just read a 3-minute summary of a 53-minute episode.

Get Business Of Biotech summarized like this every Monday — plus up to 2 more podcasts, free.

Pick Your Podcasts — Free

Keep Reading

Books, tools, and gear mentioned in this episode

SignalCast may earn commission on purchases via these links.

Tools

  • BioSeqrBy guest

    by Seek Labs

    SeekLabs' BioSeqr system maps 145 infectious diseases across 69,000+ influenza strains and roughly 3 billion data points, cross-referenced against 170,000 organisms to eliminate off-target risks.
  • PTAPBy guest

    by Seek Labs

    SeekLabs' PTAP platform uses CRISPR not to edit host genes but to chop up and eliminate viral DNA and RNA directly, lowering viral load so the immune system can respond faster.

More from Business Of Biotech

We summarize every new episode. Want them in your inbox?

Similar Episodes

Related episodes from other podcasts

Explore Related Topics

This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.

Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.

You're clearly into Business Of Biotech.

Every Monday, we deliver AI summaries of the latest episodes from Business Of Biotech and 192+ other podcasts. Free for one show.

Start My Monday Digest

No credit card · Unsubscribe anytime